Diseases in Infants and Children The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal
S. Pelton,J. Klein
Abstract:Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In June 2000, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommended the universal administration of pneumococcal conjugate vaccine for all children 23 months of age and younger and for children 24 to 59 months of age who are at high risk for serious pneumococcal disease. Since then, >23 million doses have been administered in the United States. Postlicensure surveillance of invasive pneumococcal disease (IPD) in the United States from the Active Bacterial Core Surveillance program at the Centers for Disease Control and Prevention and the Northern California Kaiser Permanente Vaccine Study Center has reported a decline in IPD and in pneumococcal disease incidence as a result of vaccine serotypes, respectively. During this period, issues critical to the long-term success of PCV7 have become more relevant: Will PCV7 be as effective in groups of children who are at high risk for IPD as in healthy children? Will nonvaccine types replace vaccine serotypes in the nasopharynx and in disease? Why are the results of the clinical trials different for IPD and for acute otitis media? How many doses of PCV7 and what concentrations of antibody are necessary for protection? Will universal administration of PCV7 to children younger than 2 years reduce antimicrobial drug resistance and alter prescribing patterns of physicians for febrile infants? Have there been unanticipated adverse events or benefits observed? The purpose of this report is to review the current data available to address these questions and to identify gaps that will require additional knowledge to determine the ultimate value of pneumococcal conjugate vaccines in reducing the burden of pneumococcal disease in infants and children. Pediatrics 2002;110:805–814; pneumococcal disease, pneumococcal vaccine, conjugate vaccine, carriage, serotypes. ABBREVIATIONS. PCV, pneumococcal conjugate vaccine; IPD, invasive pneumococcal disease; NCKP, Northern California Kaiser Permanente; HIV, human immunodeficiency virus; NP, nasopharyngeal; PPV, pneumococcal polysaccharide vaccine; ELISA, enzyme-linked immunosorbent assay; OPA, opsonophagocytic activity; MnCC, meningococcal group C conjugate vaccine; Hib; Haemophilus influenzae type b; DTP, diphtheria-tetanus-pertussis. The first pneumococcal vaccine that is safe and effective in infants and toddlers was approved by the US Food and Drug Administration in February 2000. The introduction of the heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar; Wyeth, Radnar, PA) is the culmination of 100 years of pneumococcal vaccine development. In clinical trials, the PCV was demonstrated to be effective in prevention of serotype-specific invasive pneumococcal disease (IPD), pneumonia, and acute otitis media.1,2 By December 2001, 23 million doses had been distributed throughout the United States (Frank Malinoski, Wyeth, personal communication). Postlicensure data from the Active Bacterial Core Surveillance program at the Centers for Disease Control and Prevention and the Northern California Kaiser Permanente (NCKP) Vaccine Study Center indicate a decline in IPD throughout the United States and in pneumococcal disease incidence for vaccine serotypes within the Kaiser Permanente System, respectively.3,4 The reduction in IPD was predicted from the clinical trials previously reported; however, important questions have been raised about the longterm efficacy of the vaccine.1,5 Will PCV7 be as effective in high-risk populations (eg, immunocompromised children [eg, human immunodeficiency virus (HIV), sickle cell disease]; premature infants; children of African American, Native American, and Alaskan Native descent) as in healthy populations? Will nonvaccine serotypes replace vaccine serotypes in nasopharyngeal (NP) carriage and disease, and why are the implications for otitis media different from IPD? How many doses of PCV7 and what concentrations of antibody are necessary for protection against IPD? Will there be unanticipated adverse events or benefits from immunization with PCV7? Finally, what evaluations should the physician undertake for the immunized child who has IPD? The purpose of this report is to summarize current data and suggest answers to these questions that will determine the ultimate value of conjugate vaccines in reducing the burden of pneumococcal diseases in infants and children. WILL PCV7 BE EFFECTIVE IN POPULATIONS AT HIGHEST RISK FOR IPD? The incidence and distribution of IPD in certain high-risk populations differ from those found in otherwise healthy children. For children with sickle cell disease, HIV infection, or humoral antibody defiFrom the Department of Pediatrics, Boston University School of Medicine, and Department of Pediatrics, Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, Massachusetts. Received for publication Feb 1, 2002; accepted May 6, 2002. Reprint requests to (S.I.P.) Boston University School of Medicine, Boston Medical Center, 774 Albany St, Boston, MA 02118. E-mail: spelledon@ bu.edu PEDIATRICS (ISSN 0031 4005). Copyright © 2002 by the American Academy of Pediatrics. PEDIATRICS Vol. 110 No. 4 October 2002 805 at Univ Of Arizona on June 8, 2011 pediatrics.aappublications.org Downloaded from ciency, the incidence of pneumococcal disease may exceed 6 cases per 100 patient-years compared with 0.02 to 0.06 cases per 100 patient-years reported in community-based studies of healthy children.6–9 The risk for IPD in the general population begins after 3 months of age, peaks between 12 and 18 months, and then declines after 24 months of age. Children with HIV or sickle cell disease have attack rates for IPD that remain high throughout childhood (Fig 1).9 Clinical manifestations in high-risk children often include a higher proportion of cases with pneumococcal meningitis as well as greater likelihood of relapse or reinfection. Studies of pneumococcal bacteremia in US children who have HIV infection do not indicate increased mortality or a greater risk of focal disease; however, studies in children with sickle cell disease identify increased mortality.7,10,11 The challenge of preventing pneumococcal disease in these high-risk groups is further complicated by the impaired immune function observed in children with these conditions. O’Brien et al12 found responses to PCV7 in infants and toddlers with sickle cell disease comparable to those of healthy control subjects (Table 1).12–16 Goldblatt et al17 reported that a primary series of a 9-valent PCV (PCV9) administered at 6, 10, and 14 weeks to children with sickle cell disease resulted in high antibody concentrations at 7 months of age. The 23-valent pneumococcal polysaccharide vaccine (PPV23), given at 12 months of age to this cohort, elicited a booster response contrasted with the limited response to initial immunization with PPV23 at the same age. King et al13 evaluated the immune response in children who had HIV infection and were younger than 2 years to a 5-valent PCV (PCV5). Seventy-eight percent of children who had HIV infection had 1 g/mL of antibody to all 5 serotypes after 3 doses of vaccine. The response was comparable with a control group without HIV. Children with mild HIV disease were more likely to achieve antibody concentration 1 g/mL than those with advanced disease. In a second study of older children who had HIV infection (aged 2–9 years), a single dose of PCV5 also elicited a greater antibody response than PPV23; however, when compared with healthy children, the response was significantly reduced.18 The study suggests that immunogenicity to PCV5 may be limited in older children who have HIV infection presumably because of progressive immune dysfunction. These studies relied on measurement of antibody responses using an enzyme-linked immunosorbent assay (ELISA); however, when assays of functional activity have been used in adults with HIV infection, PPV23 has failed to elicit opsonophagocytic activity (OPA) to 4 of 5 serotypes evaluated.19 Immunization with PCV7 in the same population resulted in increases in OPA to only 3 of 5 serotypes after 2 doses. Whether immune reconstitution after suppression of HIV replication, which results from antiretroviral therapy, restores the functional immune response to PCVs in children requires additional study. It can be concluded from these studies that patients with sickle cell disease respond to PCV7 with functional antibody that seems to be adequate to TABLE 1. Immune Response to PCVs in Special Populations Investigator/Year/ Reference Vaccine Population No. of Doses Time of Assessment (Months) Proportion With Antibody Concentration 1 g/mL by Serotype